Physician profile
Joshua P Spanogle
NPI 1750564407
$1,200.90
in general payments reported to CMS, 2019-2025
10 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $71.67 · 2021: $21.33 · 2023: $176 · 2024: $235 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.26 | 2019-2025 | |
| Mimedx Group, INC. | $238.52 | 2024-2025 | |
| Organogenesis INC. | $187.31 | 2023-2025 | Novachor, Affinity, Puraply |
| Genentech USA, INC. | $146.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2023 | Sotyktu |
| Allergan, INC. | $123.49 | 2019 | |
| Amgen INC. | $25.43 | 2020 | |
| Lilly USA, LLC | $21.33 | 2021 | |
| Genzyme Corporation | $20.91 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.99 | 2025 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Spanogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.